SITC initiatives are programs and projects that have been developed beyond the annual educational programs regularly held by the society. Projects are ongoing initiatives spearheaded or sponsored by the society.
Here is a list of completed SITC projects.
iSBTc* Clinical Endpoint and Response Criteria Working Group
2008 – 2009
This working group sponsored by the Society was formed to address the question of whether a different approach to tumor response was more appropriate than traditional models in trials evaluating biologic agents and to investigate whether a different approach is more appropriate in trials evaluating biologic agents.
2009 SITC-FDA Taskforce on Immunotherapy Biomarkers
2008 – 2009
In 2008, SITC joined forces with the FDA and other major cancer organizations in evaluating the use of biomarkers in clinical trials. This Taskforce focused on the unique issues related to immunologic monitoring assays as well as novel methodologies for assessing the immune landscape in cancer.
Foundation for NIH Biomarkers Consortium
2006 – 2010
The Society has played vital role in the Consortium’s efforts in development and regulatory qualification of these biomarkers for use in developing effective new treatments for major diseases. Dr. Ena Wang, MD served as the official liaison to the organization and represented the Society as a member of the Consortium’s Cancer Steering Committee.
iSBTc* Cancer Vaccine Clinical Trials Working Group
2004 – 2005
SITC and Cancer Vaccine Consortium (CVC) leaders gathered to formulate the Cancer Vaccine Clinical Trials Working Group (CVCTWG). The goal of this group was to help move cancer vaccines through the clinical development process and getting them to patients. An outcomes report of this group was given at the SITC-CVC Workshop. To view this report, click here.
*The Society for Immunotherapy of Cancer was formerly the International Society for Biological Therapy of Cancer (iSBTc).